Keyphrases
Randomized Trial
100%
Active Immunization
100%
Human Colon Cancer
100%
Risk Reduction
27%
Stage II Colon Cancer
27%
Overall Survival
18%
Colon Cancer
18%
Human Tumor Cells
18%
Recurrence-free Survival
18%
Vaccination
18%
Free-running Period
18%
Recurrence-free
18%
Clinical Benefit
9%
Resection
9%
Adjuvant Therapy
9%
Cure Rate
9%
Prospective Randomized Trial
9%
Recurrence Rate
9%
Intention-to-treat
9%
After Surgery
9%
Significant Benefit
9%
Extent of Disease
9%
Surgical Resection
9%
By Stages
9%
Stage III Disease
9%
Adverse Reactions
9%
Stage III Colon Cancer
9%
BCG Vaccine
9%
Booster Vaccination
9%
Medicine and Dentistry
Immunotherapy
100%
Colon Carcinoma
100%
Recurrent Disease
63%
Disease
27%
Risk Reduction
27%
Overall Survival
18%
Surgery
18%
Recurrence Free Survival
18%
Autologous Tumor Cell
18%
Adverse Event
9%
Adjuvant Therapy
9%
Intention-to-Treat Analysis
9%
Mycobacterium Bovis BCG
9%
BCG Vaccine
9%
Pharmacology, Toxicology and Pharmaceutical Science
Immunotherapy
100%
Colon Carcinoma
100%
Recurrent Disease
63%
Disease
27%
Neoplasm
18%
Overall Survival
18%
Recurrence Free Survival
18%
Adverse Event
9%
Mycobacterium Bovis BCG
9%
BCG Vaccine
9%
Immunology and Microbiology
Immunotherapy
100%
Colon
100%
Tumor Cell
18%
Overall Survival
18%
Recurrence Free Survival
18%
BCG Vaccine
9%
Mycobacterium Bovis BCG
9%